Replay available

Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2023 Earnings Call

Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2023 earnings call, held 2023-08-14. Watch the replay and read the transcript on 6ix.

Mon, August 14, 2023 at 8:00 AMendedReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2023 Earnings Call
Company
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)
Period
Q2 2023 earnings call
Date
Mon, Aug 14, 2023, 8:00 AM ET
Replay
Watch the replay on this page · 45 min
Results news release
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update · Mon, Aug 14, 2023

On 6ix: 6ix.com/event/acurx-pharmaceuticals-inc-acxp-q2-2023-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:01 Greetings and welcome to the Acurex Pharmaceuticals to discuss second quarter 2023 financial results and business update. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Rob Shawah, Chief Financial Officer. Thank you, sir. You may begin.

0:40 Thank you. Good morning and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the second quarter of 2023, which is available on our website at accorexpharmaceuticals.com. Joining me today is Dave Lucci. President and CEO of Acorex, who will give a corporate update and outlook for 2023. After that, I'll provide some highlights of the financials from the quarter ended June 30th, and then turn the call back to Dave for his closing remarks. Joining me as a reminder, during today's call, we'll be making certain forward looking statements. These forward-looking statements are based on current information, assumptions, estimates, and projections about future events that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

1:41 Investors should consider these risks and other information described in our filings made with the Securities and Exchange Commission, including our quarterly report on Form 10-Q which we filed on Friday, August 11th, 2023. You are cautioned not to place undue reliance on these forward-looking statements and AccuRx disclaims any obligation to update such statements at any time in the future. This conference call contains time-sensitive information that's accurate only as of the date of this live broadcast, today, August 14th, 2023. Agra X undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date and time of this conference call.

2:30 I'll now turn the call over to Dave Lucci. Dave?

2:35 Thanks, Rob. Good morning, everyone, and thanks for joining us to review our financial results for the second quarter of 2023 and also to cover some recent updates. Then we'd be pleased to take any questions. In the second quarter of 2023, we continue to enroll more patients in the Phase 2B clinical trial of our lead antibiotic candidate, Ibezopolstat, for the treatment of patients with C. difficile infection, or CDI. We're pleased to report we now have enrolled 31 patients in the Phase 2B trial, so only five more patients need to be enrolled to trigger interim data review by an independent data monitoring committee that we appointed in the first quarter of 23 for this purpose. The IDMC will review the data upon the 36 patients being evaluated for the primary endpoint of clinical cure at the end of treatment and promptly provide its recommendation either to early terminate the 2B trial, as we had done with the Phase 2A trial, or alternatively to continue enrolling. We'll report the IDMC recommendation after the interim review of the data. If the IDMC recommends early termination of the 2B trial, will promptly report the top-line data on the primary endpoint and safety data when the 36th enrolled patient completes treatment. We anticipate completing enrollment of the 36 patients for the interim review in the coming month or two.

4:04 Operationally, we're pleased to report that the blind and observed data from the Phase 2b trial has been exceptional, and the trial is proceeding as expected with no safety signals reported to date. The Phase IIb Trial Protocol includes an exploratory endpoint comparing the impact on the microbiome between ibezopolstat and standard of care oral vancomycin. In the event non-inferiority of ibezopolstat to vancomycin is demonstrated, further analysis will be conducted to test for superiority. Due to slower than expected enrollment during the COVID-19 pandemic and its aftermath, We did expand the number of trial sites participating in the 2B trial from the initial 12 sites up to 28 sites, as we now have, and have increased support to higher enrolling sites, resulting in increased screening in the past couple of months.

4:59 In March 2023, the FDA accepted our protocol amendment to our IND, which will allow an independent data monitoring committee to review the interim data that's been pre-cleared with the FDA. We remain particularly excited about the dual impact of ibuprofen at the same time to treat the acute infection, the C. diff infection, while appropriately managing the long-term care of each patient's microbiome, which we believe is exceptional for antibiotic therapy. Other key highlights from the second quarter of 23, or in some cases shortly thereafter, include the following. In April of this year, two presentations were made at the 33th Annual European Congress of Clinical Microbiology and Infectious Disease, or ECMID, in Copenhagen.

5:47 First, a scientific poster entitled, Novel Pharmacology and Susceptibility of Ibezopulsat Against C. diff Isolates with Reduced Susceptibilities to C. diff Directed Antibiotics, end quote, was presented by Dr. Kevin Geary, Professor and Chair, University of Houston College of Pharmacy, and the principal investigator for microbiome aspects of our Ibezopolstat clinical program. Dr. Gary's work demonstrated that Ibezopolstat's mechanism of action is not only bactericidal to C. diff, but also could inhibit some of its viral mechanisms, meaning its capability to cause disease. Dr. Gary also noted that C. diff strains with reduced susceptibility Any of the other antibiotics used to treat C.

6:33 diff, metronidazole, vancomycin, or finacomycin, those C. diff strains were susceptible to Ibezopulstat. So just to say it again, Ibezopulstat is able to successfully kill C. diff bacteria that in many cases is resistant to all the other antibiotics used to treat C. diff currently. Ibezopulstat's antiviral effect, namely reduced flagellar movement, of the C. diff. organism was a positive, unexpected finding, reflecting the unique mode of action in inhibiting DNA-PAL3C. In the second of two presentations at ECMID, ACRES' executive chairman, Bob DeLuccia, presented an update regarding the company's preclinical systemic oral and IV program for the treatment of other gram-positive infections caused by MRSA, VRE, and DRSP in the pipeline corner featured session at ECMID.

7:30 organized by Dr. Ursula Ferretzbacher, a world-renowned microbiology expert involved in antibacterial drug research, discovery and development strategies, and policies for clinical and public health needs. Bob summarized the progress of the company's grant-positive Select Spectrum program. Both posters are available on our website.

7:51 Additionally, in the third quarter, we were notified by CARB-X that we did not receive funding approval and their recently closed 23 omnibus funding round for our second antibiotic candidate, ACS375C, which is in preclinical development. We did appeal this decision based on certain modifications to the scope of our program. However, CARB-X governance structure did not allow for acceptance of an appeal process. CARB-X noted that the 23 round of funding was very competitive and that their scientific advisory board was enthusiastic about AL3C as the bacterial target of our molecules and that the sufficiently good PK and safety properties of the compounds that we have justified the proposed lead optimization plan.

8:40 CARBETs encourage us to reapply for future requests for proposals or RFPs that CARBETs will continue to promulgate from time to time for funding consideration. While this news was disappointing, we will continue to monitor and apply for grants from all funding sources as they become available. Now looking forward just a bit, the upcoming Antimicrobial Resistance Congress is next month. It will convene its annual meeting in Philadelphia where experts in the field from both the public and private sectors weigh in on the latest innovations to address antimicrobial resistance. This is the world's largest conference for all stakeholders combating antimicrobial resistance, and our Executive Chairman will speak at the Innovation Showcase section of the conference on September 7 and will present an update entitled Novel DNA Pol3C Inhibitors for Gram-Positive Bacterial Infections, Preparing for the Next Pandemic, end quote. After the presentation, it will be available on our website.

9:47 In addition, we have ID Week coming up. The Infectious Disease Society of America will convene its annual meeting called ID Week in Boston, October 11-15. Accurates will be featured at two scheduled events. First, an oral presentation by Dr. Kevin Geary will be given on October 14th entitled, Elucidating the Gram-Positive Selective Spectrum Activity of Ibexipulstat Secondary Analysis from the Phase IIa Trial. and secondly, ACRES will present at the symposium entitled New Antimicrobials in the Pipeline on October 12th. At the symposium, ACRES presentation will be entitled Novel DNA PIL3C Inhibitors for Gram-Positive Bacterial Infections.

10:38 After this presentation, it too will be available on our website. Now to the Pasteur Act. As we've discussed in the past, the bipartisan Pasteur Act continues to generate news and Enthusiasm in Washington, D.C. On April 27th, U.S. Senators Michael Bennett and Todd Young reintroduced the Pasteur Act to encourage innovative drug development targeting the most threatening infections, improve the appropriate use of antibiotics, and ensure domestic availability of antibiotics when needed. On July 11th, a Senate subcommittee hearing was convened, led by Senators Markey and Marshall, highlighting the need to address antimicrobial resistance to superbugs, including MRSA and C. diff. Accordingly, we're quite enthusiastic about the prospects of the Pasteur Act being passed into law on the bipartisan support, significant national spotlight, and dire need for new classes of antibiotics to treat serious and life-threatening infections.

11:44 and now back to our CFO, Rob Shawah, to guide you through the highlights of our financial results for the second quarter of 2023. Rob?

11:54 Thanks, Dave. Our financial results for the second quarter ended June 30, 2023 were included in our press release issued earlier this morning. The company ended the second quarter with cash totaling $9.1 million compared to $9.1 million as of December 31, 2022. Research and development expenses for three months ended June 30, 2023 were $1.7 million compared to $0.9 million for three months ended June 30, 2022. The increase was due to an increase in Phase IIb trial-related costs. For the six months ended June 30, 2023, Research and development expenses were $2.8 million versus $1.7 million for the six months ended June 30, 2022. The increase is due primarily to Phase IIb trial-related costs and an increase in consulting costs.

12:56 General and administrative expenses for the three months ended June 30, 2023 were $1.7 million compared to $1.7 million for the three months ended June 30, 2022. The expenses reflect a slight decrease in professional fees of $0.1 million, offset by a slight increase of $0.1 million in employee compensation-related costs. For the six months ended June 30, 2023, general and administrative expenses were $3.6 million versus $3.6 million for the six months ended June 30, 2022. The amount reflects a decrease in professional fees of $0.2 million all set by an increase of $0.2 million in employee compensation-related costs.

13:46 The company reported a net loss of $3.4 million, or $0.28 per diluted share, for the three months ended June 30, 2023, compared to a net loss of $2.6 million, or $0.26 per diluted share, for the three months ended June 30, 2022, and a net loss of $6.3 million, or $0.53 per share for the six months ended June 30, 2023, compared to a net loss of $5.3 million or $0.52 per diluted share for the six months ended June 30, 2022, all for the reasons previously mentioned. The company had 13,005,128 shares outstanding as of June 30, 2023.

14:36 With that, I'll turn the call back over to Dave.

14:40 Thanks, Rob, and to all of you joining us today. We outlined advances in several areas that we believe will spur continued momentum and growth, build on our strong fundamentals. We look forward to sustaining this momentum even during these challenging times and sharing future updates and results in the coming months. I will now open the call for any questions. Operator? Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you'd like to remove your question from the queue.

15:25 For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we pull for questions. Thank you. Our first question comes from the line of Ed Arcee with H.C. Wainwright. Please proceed with your question.

15:48 Hi, good morning, everyone. This is Thomas Yip asking a couple questions for Ed. Thank you for taking our questions. First, we'll face to face study. Hey, hey, good morning. Good to hear the update for AccuRx. So back in March, the guidance for the Phase 2B interim review was anticipated mid-year 2023. Can you outline some major factors that are behind this shift in timing and also what are some remedies that you are implementing to address it?

16:30 Okay, Thomas, I mean, I think the question is about 180 degrees in the wrong direction, I'm sorry to say. If you check your notes, I think you'll find that on May 14th, at the end of the first quarter, we guided folks that we would be done in the second half of 2023 with the 2B trial, and if anything today, we've guided folks that we're going to be done before that.

16:59 Okay, so the latest, yes, I do remember the latest guidance was second half. So you mentioned in coming months, so is that sounds more like a third quarter or early for events?

17:19 Yes, yes. So when I say before that, I mean before the end of the second half. But yeah, we do think that it will be, you know, in the coming, as I mentioned, in the coming month or two, We've had significantly better enrollment. We've plugged a new CRO into special situations, and that's starting to bear fruit, including a substantial increase in the number of patients that are screened. So maybe it's also in combination a bit with COVID being further and further behind us, and maybe some of the behavioral patterns are changing back. So in any event, whatever the cause is, we're screening more patients, and we don't think we have far to go.

18:06 Got it. And Dan, you mentioned for the Phase II B interim analysis, there's a new IBMC. Can you give some details on members on this board, and is it the same core members as the ITMC for the Phase 2A study?

18:29 Okay. So we don't give out the names of the members, but just to be clear, for the Phase 2A study, the 2A trial was early terminated on the recommendation of our scientific advisory board, which is included in our slide deck and on our website. But the Phase 2B trial for it We had to create a separate independent data monitoring committee, and these are all independent scientific experts in infectious disease, and in one case a statistician, none of which have shares in our company or get paid by our company, and they're doing this as a public service. That's the constituency of the IDMC.

19:14 It's different people in every case than those who served as scientific advisory board members. currently for the company and who opined on the 2A trial. Okay, understood. Thank you for the clarification.

19:30 Perhaps one question regarding the COVID funding. Sorry to hear that 375 not advancing to the next round. In order to be eligible for future grants, will you need a new program, or do you plan to continue 375 with the eligible?

19:53 So for each grant, whether by CARB-X or other folks like NIH, to be eligible, you have to look at the RFP, the Request for Proposal. So with CARB-X in particular, this was the first CARB-X grant RFP in years that allowed folks who are developing antibiotics that target treatment of gram-positive bacteria infections, not just gram-negative. So we were excited to see that the scope of the RFP had expanded to include sponsors like us. And we expect, based on our conversations with CARB-X, that that will continue. And as we continue to develop our drug, get through lead optimization, We think our candidacy will become more and more compelling in these challenging times for money.

20:51 I see. Okay. Perhaps one last question from us. This one is financial. It sounds like, as you mentioned earlier, the interim analysis seems to be occurring really soon. So cash runway should extend beyond that, but can you give us perhaps a more specific timeframe for approximate cash runway?

21:17 Sure, Thomas. You know, I think our cash runway is sufficient through Q3 of 24 and kind of amend some. So we're burning 2.1, 2.2 million per quarter. and that's during the quite expensive 2B trial times. So once the 2B trial is over, we should eliminate probably a million dollars of that 2.1, 2.2 million quarterly burn. So if you take 2.2 and you flatline it for four quarters, that's 8.8. So even if the 2B, you know, for some reason got extended, you know, enormously long. We'd have money through Q3, and given where we are, we probably have money all the way through 24, because the 2B will be over.

22:13 Okay, understood. Thank you again for taking our questions, and looking forward to the interim analysis for the Phase 2B study.

22:22 No problem, Thomas. If you have any other questions, just give me a call or shoot me an email, and we'll connect.

22:27 Definitely. Thank you. Thank you. Our next question comes from the line of Jason McCarthy with Maxim Group. Please proceed with your question. Hey, guys. This is Mike Lokunowicz on the line for Jason. Thank you so much for taking my questions today. No problem. Thanks for calling, Mike. Yeah, so I'd like to see if you could talk a little bit more about the specifics of the Pasteur Act. Obviously, just the validation of the problem and that, you know, Congress is paying attention to this is huge in itself. But what specifics have been suggested that could aid in clinical development and uptake of new anti-infectives, and particularly as it relates to Acurex?

23:15 Sure. No problem, Mike. This is, you know, the This is the transitional piece of legislation that would completely redefine the antibiotic sector in the United States. Just to be perfectly clear, this puts antibiotics back on par profit-wise, revenue-wise with cancer drugs and diabetes drugs, neurological drugs for ALS and other neurological disorders. It's a game changer. What the Pasteur Act does generally, and there's also a Pasteur Lite that I'll get to, the Pasteur Act, if approved, is a pull incentive, similar to the pull incentive already approved and made law in the UK a few years back.

24:05 What the pull incentive does is it says, hey, sponsors of new antibiotics and those who invest in them, if you invest in an antibiotic, if you take your time to develop for a life-saving or serious clinical indication that is a new class of antibiotics, not just a new generation of amoxicillin or an old class. If that's what you have, we'll pay for Phase 3, including all the manufacturing for Phase 3, and we'll give you between $750 million and $3 billion over a 10-year period of time in order to stockpile your antibiotic at public health facilities over a 10-year period of time under a license agreement with Health and Human Services.

24:58 Pasteur Lite would be basically half of that. So it would be $375 million minimum up to $1.5 billion for each sponsor of QIDP, an antibiotic that treats Thank you for joining us. and the amount between $375 and $1.5 billion over 10 years under past sewer light will be determined by HHS based on a formula to be provided in the law. And basically that formula will try to get to the savings to the public health system in the United States by having your antibiotic approved to treat these serious and life-threatening infections.

26:15 So in the case of C. difficile, the reinfection market in C. difficile has a price tag of $4.7 billion to U.S. public health every year. So patients that have recurrent C. diff infection with the total cost of treating those reinfections from the hospitalizations to the medicines that are being used is $4.7 billion a year. So in our case, if we come out with an antibiotic that's, you know, frontline capable, treating C. diff patients with anything close to 100% cure rate and anything close to 0% reinfections, I think that would have a significant value savings to public health in the U.S.

27:06 Not the full $4.7 billion that is the cost of the reinfection market for C. diff, every year in the U.S., but it would be significant. But at the very least, it would be $375 million to us, $37.5 million a year for 10 years. So as a $30 million market cap company, you can see if we were designated as a critical need antimicrobial under the Pasteur Act, it would be an absolute game changer. Certainly, there's a lot of potential there. It's just a follow-up on the phase to me. I'd like to see if you could provide then a bit more color on the potential to possibly stop it early on efficacy, what would need to be demonstrated, and then expand a little bit on how you can use changes in the microbiome in addition to the primary endpoint to support a readout on that study.

27:58 Okay, great. No problem.

27:59 So the microbiome changes, you know, that's the easier question to answer at first. We see the full restoration of a fully healthy microbiome in RCDF patients that we've treated by the end of the third day of a 10-day treatment regimen on our drug. That's from the Phase IIa trial. We have no reason to expect that will change because of the scientific underpinning of no reinfections. Why are there no reinfections? Because we're fully restoring the microbiome. by day three of treatment. And how are we restoring the microbiome? Well, we have a very narrow spectrum antibiotic that's only able to kill C.

28:44 diff, leaving all of the other classes of healthy bacteria in the gut alone, providing them an environment where they can kind of repair themselves. Unlike the normal antibiotic like vancomycin, the standard of care, which decimates the healthy microbiome while it's curing the direct C. diff infection. Dr. Michael Silverman, David Luci, Robert DeLuccia Thank you very much.

30:05 The 31 patients that are enrolled are evaluated. The blinded observed data is tremendous. And our statisticians say if there are up to two patients who are not cures out of the 36 patients evaluated at the interim look, even if those two patients are on our side of the two-on trial, we would still be able to achieve statistical non-inferiority. So on that basis, and given we have 65 years of clinical trial data to look at for how Vanco is going to do in our trial, and you see it never gets higher than 92%, and it's been as low as 70% over 65 years, it's going to be in the kind of low 80s.

30:58 We're feeling very bullish on our possibilities at getting through this binary endpoint. And then you have to ask yourself, what's the intrinsic value of this drug in the C. diff market to big pharma? A $1.7 billion market. And with a clear shot at frontline therapy, you'd have to ask, what's that worth? And when you're asking yourself, what's that worth? You could reasonably look at for example, the Tillots Pharma acquisition of the EU rights to Merck's Fedaxomycin, the last line in the U.S., for about $125 million in 2022. That's just European rights, and we have U.S., Europe, and Japan.

31:49 And you could also look at the March 23 Sabila Pharmaceuticals deal to buy Destiny Pharma in a structured deal totaling $570 million. and that was a much earlier stage development program than we have. So the intrinsic value is quite high. We've got to get through this binary phase 2B trial readout and we're really excited about where we go from there. All right. Thank you. I really appreciate your additional insights here. No problem. Thank you, Mike. Thank you. And our next question comes from the line of Jim Molloy with Alliance Global Partners. Please proceed with your question.

32:38 Hi, good morning. Thank you for taking my question. I had a question on the CARB-X. You walked through sort of what next steps are for 375C. Is there an opportunity to move forward absent the CARB-X funding? And when did CARB-X notify you guys that They weren't going to proceed forward with 375.

33:02 The CARBETS folks notified us kind of probably a couple of weeks ago, late in July. And we followed up with questions and an appeal. And that process took a couple of weeks to kind of meander through. So the timing is perfect for this call. But the program never stopped. We continue to evaluate and work on the lead optimization process, which is why I say that as that process continues and gets to completion, we're going to have a stronger and stronger chance at the next CARB-X RFP that comes out that we get picked up within the scope of that RFP.

33:50 If it includes gram-positive treating antibiotics, will apply again with a more compelling package. And we feel that because we weren't rejected back in April like most others were, we feel we're kind of on the bubble. We just have to kind of push forward, present a little bit more R&D, and then we feel that we'll be successful.

34:19 I wanted to state the next opportunity to apply for CARB-X funding will occur. It sounded like it was a bit up in the air.

34:27 They do an RFP every November. There may be other RFPs that they do, but pretty much every November they seem to come out with an RFP that we've noticed. The only question will be whether that RFP continues to include gram-positive treating antibiotics. If it does, we'll reapply in the fourth quarter and hope for positive reconsideration in April. Got it, thank you.

34:57 Then on the Phase 2b, how long for the fifth and final patient, 36th patient coming in to final data or final notification by the IDMC on what next steps are?

35:14 So if you assume the 36th patient came in today, that 36 patients would be out of the study 10 days from today and they would be evaluated for the primary endpoint two days thereafter, so 12 days from today. After that, the IDMC will meet day 13, day 14, like that, and come back with their recommendation. As soon as we have that recommendation, so basically a couple of weeks, as soon as we have that recommendation from the IDMC, we'll put out a press release Well, first we'll put out a press release that we got to the 36th patient. The second press release will be the IDMC recommendation and the company's decision to take or not take the recommendation.

36:04 Of course, we'll probably take it. So that would be the second press release. And then assuming the IDMC recommends that we early terminate, then when that 36th patient is completely out of the trial and we have a final study report, will put out a press release with all of the data on the primary and secondary endpoints.

36:31 And it certainly seems a positive sign for potential early termination, given the historical data on Vanco and the data you guys have seen, even though it's still blinded. But assuming you have to run the 36, you're only halfway through, presumably you have to run it through the 72nd patient. What's the thinking going forward on that, and what's the ability of Acurex to fund that second half of this trial if it's needed?

37:03 Yeah, I mean, if we have to go to the 72, we'll be able to continue to fund the trial in the ordinary course. As I mentioned, if we have to keep paying $2.2 million per quarter for our ongoing costs, that's fine. We could raise a tiny amount of money, $5 million, whatever the number might be, just to pick up some international sites and pay for them. High-enrolling Eastern European sites and Canadian sites, just following up on how did Summit Therapeutics manage to enroll so quickly during COVID. In our estimation, that's kind of how they did it. They opened up to international sites. in high and rolling areas that weren't terribly impacted by the pandemic.

37:54 So that's what we would do if we had to do another 36. It would be adding new trial sites, international trial sites, and, you know, kind of expanding in that way to make sure it didn't take as long.

38:08 Understood. And then what, on the past year, I know it's a bit out of your, it's completely out of your control, but what should we be looking for for the next catalyst to potentially give an idea of what might be coming out of this, if anything, on the Pasteur or Pasteur Lite.

38:26 Yeah, you know, I mean, it's funny, you know, I mean, as you know, as investors are aware, when you're dealing with the government and the, you know, kind of movements and, you know, entities of the government, when things get approved, you know, it's just extremely difficult to benchmark and to handicap. The Antimicrobial Working Group meets every month and continues, of which we're a member. They continue to kind of go back and forth on when it would be that Pasteur would be passed and whether it would be Pasteur or Pasteur Lite. The best we can say is it's looking very positive for Pasteur Lite, not for Pasteur. Pasteur Lite by itself is like a six-run home run for us.

39:12 And we think that public health needs it. That's been made very clear by those in public health. It's already approved in the UK, which paves the way for us. We can't speak as to timing, but wouldn't it be ironic if this delay in the enrollment leads us to an M&A situation where Pasteur is passed and we can capitalize on it before we were able to do a transaction? That would be great. Jim, do we still have you? Sorry, excuse me. If you would like to ask a question, please press star one on your telephone keypad.

40:01 Our next question comes from the line of Nick Meyer, who is a private investor. Please proceed with your question.

40:10 Good morning, David. Quick question on the IDMC and the data readout. Does the FDA have to approve the IDMC's recommendation or are they not involved?

40:25 Hi, Nick. Good morning. Thanks for your question. No, the FDA is not involved any longer. They had to approve. Well, they didn't have to approve. They had to accept our amendment to our trial protocol and our related IND. in order to provide for this IDMC mechanism, but that's it. The IDMC is free to make whatever recommendation that they feel is most appropriate, and the FDA won't review any of it until we get to an application for FDA approval.

41:02 Okay, and then the IDMC is only looking at the primary metric, which is clinical cure. They're not all looking at the secondary metrics at all? for their recommendation?

41:14 Well, they're only looking at the end of treatment, but also the safety.

41:23 Yep, that makes sense. And then the last question I have is, what is the value pivot between if you were to do an M&A before Phase III or going to an interim look on the first leg of Phase III? What is your consideration there?

41:44 Well, you know, I would take that question and reference the bio industry guide. You know, what they have is like a blue book for personal injury lawyers where they have a percentage likelihood of FDA approval when you're in preclinical phase one, phase two, phase three for any disease indication, including infectious disease, right? first of two phase three registration studies and show consistent data with everything before it, you know, you have about a 30% likelihood of failure in phase three for all antibiotics.

42:30 When you zero in on antibiotics that treat gram-positive infections instead of gram-negative, you know, that's probably down to a 10% or 15% failure rate. And you could probably chop that failure rate in half When you present interim data on the first half of the first of the two phase threes. So it would be a significant value enhancement. And, you know, that might be offset by having an even worse stock market then than we have when we come out with the 2B data. It's hard to say. The biggest bogey will be if the Pasteur Act is passed and we get designated as a critical need antimicrobial. That is an absolute game changer, even under Pasteur Lite, that would have a dramatic impact on what we're able to sell for.

43:18 Now, we could sell before getting that designation. So, hypothetically, if Pasteur is passed and we're not yet designated, even though it would seem that we would be, you know, one of the most qualifying of potential candidates, it could be a contingent value right in a deal that could be negotiated before prior to having the designation, and we would just have to consider the various factors as we continue to talk to potential partners.

43:49 Okay, but is there a specific market value that you're looking for, or is that going to be duty-determined?

44:00 No, it's all going to depend, and we're just going to have to evaluate that we may get, and consider the intrinsic value of the program and whether or not the offer is within a range that is acceptable. Of course, we'll have advice from the banking side. Likely, a fairness opinion will be involved to make sure that our bankers think that whatever terms are being offered and the board accepts are fair to go into that acceptance by the board. It's all going to be deal-related and and the board doesn't, if we're trading at a low valuation and someone's trying to undercut real value, the board can say no.

44:49 Yep, that makes sense. All right, thank you for answering the questions. Appreciate it.

44:54 No problem. Thank you, Nick. Thank you. We have reached the end of our question and answer session. And with that, this will conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.

Follow Acurx Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Nick Meyer

Private Investor

Dave Lucci

President and CEO

Thomas Yip

Analyst, H.C. Wainwright

Rob Shawah

Chief Financial Officer

Jim Molloy

Analyst, Alliance Global Partners

More from Acurx Pharmaceuticals, Inc.